, Volume 12, Issue 4, pp 258–273 | Cite as

Antihistamines: Pharmacology and Clinical Use

  • David S. Pearlman
Review Article


Antihistamines are a diverse group of drugs which possess the ability to inhibit various histaminic actions. By and large, they bear a certain structural resemblance to histamine, and act principally to prevent histamine-receptor interaction through competition with histamine for histamine receptors. Consequently, they are helpful therapeutically in preventing, rather than reversing, histaminic actions. Individual antihistaminic drugs act to inhibit histaminic action at one or another histamine receptor (H1 or H2-receptor), but not at both receptors.

The large number of antihistaminics which have been available for many years and employed chiefly as ‘antiallergic’ drugs are classified as H1-receptor inhibitors; they are most effective therapeutically in inhibiting manifestations of histamine-induced wheat and erythema formation and pruritus. H2-receptor inhibitors, agents which are able to inhibit histamine-induced gastric acid secretion, have been developed more recently. Antihistaminics in general and H1-receptor inhibitors in particular, exert a wide variety of pharmacological activities. Their use is frequently accompanied by undesirable side-effects, notably CNS depression, dryness of mucous membranes, and gastrointestinal effects.

Used judiciously and in proper dosage, antihistaminic drugs are helpful in the control of allergic disorders, allergic rhinitis and urticaria in particular; newly developed H2-receptor inhibitors show therapeutic promise in the treatment of peptic ulceration.


Histamine Allergic Rhinitis Chronic Urticaria Histamine Receptor Allergic Disorder 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aliëns, E.J.: Simonis, A.M. and van Rossum, J.M.: Drugreceptor interaction: action of one or more drugs with one receptor system; in Ariëns (Ed), Molecular Pharmacology. The Mode of Action of Biologically Active Compounds; Medicinal Chemistry Series, Vol. 1, p. 119–286 (Academic Press, New York 1964).Google Scholar
  2. Arbesman, C.E.: The pharmacology, physiology, and clinical evaluation of the new antihistaminic drugs (Pyribenzamine and Benadryl). New York State Journal of Medicine 47: 1775–1781 (1947).PubMedGoogle Scholar
  3. Arunlakshana, O.: Histamine release by antihistamines. Journal of Physiology 119: 47–48P(1953).Google Scholar
  4. Ash, A.S.F. and Schild, H.O.: Receptors mediating some actions of histamine. British Journal of Pharmacology and Chemotherapy 27: 427–439 (1966).PubMedGoogle Scholar
  5. Barth, H.; Niemeyer, I. and Lorenz, W.: Studies on the mode of action of histamine H1 and H2-receptor antagonists on gastric acid methyltransferase. Agents and Actions 3: 138–147 (1973).PubMedGoogle Scholar
  6. Black, J.W.; Duncan, W.A.M.; Durant, G.J.; Ganellin, C.R. and Parsons, M.E.: Definition and antagonism of H2-receptors. Nature 236: 385–390 (1972).PubMedGoogle Scholar
  7. Black, J.W.; Duncan, W.A.M.; Emmett, J.C.; Ganellin, C.R.; Hesselbro, T. and Parsons, M.E.: Metiamide — an orally active histamine H2-receptor antagonist. Agents and Actions 3: 133–137 (1973).PubMedGoogle Scholar
  8. Black, J.W. and Spencer, K.E.V.: Metiamide in systematic screening tests; in Wood and Simkins (Eds) International Symposium on H2-receptor Antagonists, p.23-27 (Smith Kline and French, Welwyn Garden City 1973).Google Scholar
  9. Blanton, W.B. and Owens, Jr., M.E.B.: Granulocytopenia due probably to “pyribenzamine”. Journal of the American Medical Association 134: 454–455 (1947).PubMedGoogle Scholar
  10. Booij-Noord, H.; Orie, N.G.M.; Berg, W. and de Vries, K.: Protection tests on bronchial allergen challenge with disodium cromoglycate and thiazanium. Journal of Allergy 46: 1–11(1970).PubMedGoogle Scholar
  11. Bourne, H.C.; Lichtenstein, L.M. and Melmon, K.L.: Pharmacologic control of allergic histamine release in vitro: Evidence for an inhibitory role of 3′,5′-adenosine monophosphate in human leukocytes. Journal of Immunology 108: 695–705 (1972).Google Scholar
  12. Bourne, H.R.; Melmon, K.L. and Lichtenstein, L.M.: Histamine augments leukocyte cyclic AMP and blocks antigenic histamine release. Science 173: 743–745 (1971).PubMedGoogle Scholar
  13. Bovet, D. and Staub, A.M.: Action protectrice des ethers phenoliques au cours de l’intoxication histaminique. Comptes Rendues des Seances de la Societe Biologique 124: 547–549(1937).Google Scholar
  14. Bovet, D.: Introduction to antihistamine agents and antergan derivatives. Annals of the New York Academy of Sciences 50: 1089–1126 (1950).PubMedGoogle Scholar
  15. Brimblecombe, R.W.; Duncan, W.A.M.; Durant, G.J.; Ganellin, C.R.; Parsons, M.E. and Black, J.W.: The pharmacology of cimetidine, a new histamine H2-receptor antagonist. British Journal of Pharmacology 53: 435–436P(1975).Google Scholar
  16. Byck, R.: Drugs and the treatment of psychiatric disorders; in Goodman and Gilman (Eds) The Pharmacological Basis of Therapeutics, p. 152–200, 5th ed. (Macmillan, New York 1975).Google Scholar
  17. Cahen, R.L.: Evaluation of teratogenicity of drugs. Clinical Pharmacology and Therapeutics 5: 480–514 (1964).PubMedGoogle Scholar
  18. Cahn, M.M. and Levy, E.J.: Ultraviolet light factor in chlorpromazine dermatitis. Archives of Dermatology 75: 38–40(1975).Google Scholar
  19. Celestin, L.R.; Harvey, V.; Saunders, J.H.B.; Wormsley, K.G.; Fonest, J.A.H.; Logan, R.F.A.; Shearman, D.J.C.; Fermont, D.; Haggie, S.G.; Wyllie, J.H.; Albinus, M.; Thompson, M.H.; Venables, C.W.; Burland, W.L.; Duncan, W.A.M.; Hawkins, B.W. and Sharpe, P.C.: Treatment of duodenal ulcer by metiamide. A multicentre trial. Lancet 2: 779–781 (1975).Google Scholar
  20. Chinn, H.I. and Smith, P.K.: Motion sickness. Pharmacological Reviews 7: 33–82 (1965).Google Scholar
  21. Churchill, J.A. and Gammon, G.D.: The effect of antihistaminic drugs on convulsive seizures. Journal of the American Medical Association 141: 18–21 (1949).PubMedGoogle Scholar
  22. Cochrane, C.G. and Koffler, D.: Immune complex disease in experimental animals and man. Advances in Immunology 16: 185–264 (1973).PubMedGoogle Scholar
  23. Cohlon, S.Q.: The teratogenicity of drugs in man. Pharmacology for Physicians 3: 1–5 (1969).Google Scholar
  24. Conney, A.H.; Schneidman, K.; Jacobson, J. and Kuntzman, R.: Drug induced changes in steroid metabolism. Annals of the New York Academy of Sciences 123: 98–107 (1965).PubMedGoogle Scholar
  25. Cook, T.J.; MacQueen, D.M.; Wittig, HJ.; Thornby, J.I.; Lantos, R.L. and Virtue, CM.: Degree and duration of skin test suppression and side effects with antihistamines. Journal of Allergy and Clinical Immunology 51: 71–77(1973).PubMedGoogle Scholar
  26. Criep, L.H. and Aaron, T.H.: Neoretramine: an experimental and clinical evaluation in allergic states. Journal of Allergy 19: 215–224 (1948).PubMedGoogle Scholar
  27. Dannenberg, T.B. and Feinberg, S.M.: The development of tolerance to antihistamines. A study of the quantitative inhibiting capacity of antihistamines on the skin and mucous membrane reaction to histamine and antigens. Journal of Allergy 22: 330–339 (1951).Google Scholar
  28. Done, A.K.: Developmental pharmacology. Clinical Pharmacology and Therapeutics 5: 432–479 (1964).PubMedGoogle Scholar
  29. Douglas, W.W.: Histamine or antihistamines; 5-hydroxytryptamine and antagonists; in Goodman and Gilman (Eds) The Pharmacological Basis of Therapeutics, 5th ed. p.590–629 (Macmillan, New York 1975).Google Scholar
  30. Duff, F.; Patterson, G.C and Whelan, R.F.: The effect of intra-arterial antihistamines on the hyperaemia following temporary arrest of the circulation in the human forearm. Clinical Science 14: 276–283 (1955).Google Scholar
  31. Durant, G.J.; Emmett, J.C and Ganellin, C.R.: Some chemical aspects of H2-receptor antagonists; in Wood and Simkins (Eds) International Symposium on Histamine H2-Receptor Antagonists, p.13–21 (Smith Kline and French, Welwyn Garden City 1973).Google Scholar
  32. Editorial: Multicentre study on Metiamide. Lancet 2: 802–803(1975).Google Scholar
  33. Empey, D.W.; Bye, C; Hodder, M. and Hughes, D.T.D.: A double-blind crossover trial of pseudoephedrine and triprolidine, alone and in combination for the treatment of allergic rhinitis. Annals of Allergy 34: 41–46 (1975).PubMedGoogle Scholar
  34. Englesher, D.L.: Antihistamine drugs in asthma and hay fever. New York State Journal of Medicine 47: 1696 (1947).Google Scholar
  35. Eyre, P. and Wells, P.W.: Histamine H2-receptors modulate systemic anaphylaxis: a dual cardiovascular action of histamine in calves. British Journal of Pharmacology and Chemotherapeutics 49: 364–367 (1973).Google Scholar
  36. Feinberg, S.M.: Antihistamine Therapy. Experimental and clinical correlation. Annals of the New York Academy of Sciences 123: 1186–1200(1950).Google Scholar
  37. Feinberg, S.M. and Friedlaender, S.: Relief of dermographism and other urticarias of histamine origin by a synthetic benzhydrylalkamine ether. Journal of Allergy 16: 296–298 (1945).PubMedGoogle Scholar
  38. Feinberg, S.M. and Friedlaender, S.: Histamine antagonists. IV. Pyridil-N’ benzyl-N-demethylethylenediamine (Pyribenzamine) in symptomatic treatment of allergic manifestations. American Journal of the Medical Sciences 213: 58–60 (1947).PubMedGoogle Scholar
  39. Feinberg, S.M.; Malkiel, S. and Feinberg, A.R.: The Antihistamines: Their Clinical Application (Yearbook, Chicago 1950).Google Scholar
  40. Feinberg, A.R.; Pruzansky, J.J.; Feinberg, S.M. and Fisherman, E.W.: Hydroxyzine (Atarax) in chronic urticaria and in allergic manifestations. Journal of Allergy 29: 358–361 (1958).PubMedGoogle Scholar
  41. Fitzpatrick, R.J.; Oer, L.M. and Stubbart, Fj.: Antihistamines as local anesthetic agents for urethral manipulation. Journal of the American Medical Association 150: 1092–1094 (1952).PubMedGoogle Scholar
  42. Forrest, J.A.H.; Shearman, D.J.C.; Spence, R. and Celestin, L.R.: Neutropenia associated with metiamide. Lancet 1: 392 (1975).PubMedGoogle Scholar
  43. Franz, D.N.: Drugs for Parkinson’s disease; centrally acting muscle relaxants; in Goodman and Gillman (Eds) The Pharmacological Basis of Therapeutics, p.152–200, 5th ed. (Macmillan, New York 1975).Google Scholar
  44. Glover, W.E.; Carroll, P.R. and Latt, N.: Histamine receptors in human temporal and rabbit ear arteries; in Wood and Simkins (Eds) International Symposium on Histamine H2-Receptor Antagonists, p.169–174 (Smith Kline and French, Welwyn Garden City 1973).Google Scholar
  45. Gold, W.M.: Cholinergic pharmacology in asthma; in Austen and Lichtenstein (Eds) Asthma, Physiology, Immuno-Pharmacology and Treatment, p.169–182 (Academic Press, New York 1973).Google Scholar
  46. Goth, A.: Medical Pharmacology, Tranquilizer drugs, chapter 15, p.197–215, 3rd ed. (Mosby, St. Louis 1966).Google Scholar
  47. Grayson, L.D. and Shair, H.M.: Atopic dermatitis. III. The correct choice of antihistaminic agents. Annals of Allergy 21: 168–170(1963).PubMedGoogle Scholar
  48. Hägermark, Ö.: Influence of antihistamines, sedatives, and aspirin on experimental itch. Acta Dermatologica 53: 363–368 (1973).Google Scholar
  49. Håkanson, R.; Hendenbro, J.; Leidberg, G.; Rehfeld, J.H. and Stadil, F.: Activation of histidine decarboxylase by H2-receptor blockade: Mechanism of action. British Journal of Pharmacology 53: 127–130 (1975).PubMedGoogle Scholar
  50. Halpern, B.N.: Les antihistaminiques de synthese: essais de chimiotherapie des etats allergiques. Archives internationales de Pharmacodynamie et de Therapie 68: 339–408 (1942).Google Scholar
  51. Hansten, P.D.: Drug Interactions, 2nd ed. (Lea and Febiger, Philadelphia 1973).Google Scholar
  52. Hawkins, D.F.: Bronchoconstrictor and bronchodilator actions of antihistaminic drugs. British Journal of Pharmacology 10: 230–239 (1955).Google Scholar
  53. Henney, C.S.; Bourne, H.R. and Lichtenstein, L.M.: The role of cyclic 3′, 5′-adenosine monophosphate in the specific cytolytic activity of lymphocytes. Journal of Immunology 108: 1526–1534 (1972).Google Scholar
  54. Herxheimer, H.G.J.: Aleudrine and anthisan in bronchial spasm. Lancet 1: 667–671 (1948).PubMedGoogle Scholar
  55. Herxheimer, H.G.J.: Antihistamines in bronchial asthma. British Medical Journal 2: 901–905 (1949).PubMedGoogle Scholar
  56. Herxheimer, H.G.J.: The Management of Bronchial Asthma (Butterworth, London 1952).Google Scholar
  57. Hill, R.: Drugs ingested by pregnant women. Clinical Pharmacology and Therapeutics 14: 654–659 (1973).PubMedGoogle Scholar
  58. Hill, R.M.; Desmond, M.M. and Kay, J.L.: Extrapyramidal dysfunction in an infant of a schizophrenic mother. Journal of Pediatrics 69: 589–595 (1966).PubMedGoogle Scholar
  59. Isaac, L. and Goth, A.: The mechanism of the potentiation of norepinephrine by antihistamines. J. Pharmacol. exp. Ther. 156: 463–468 (1967).PubMedGoogle Scholar
  60. Johnson, G.L. and Kahn, J.B.: Cocaine and antihistaminic compounds: Comparison of effects of some cardiovascular actions of norepinephrine, tyramine and bretylium. Journal of Pharmacology and Experimental Therapeutics 152: 458–468 (1966).PubMedGoogle Scholar
  61. Karlin, J.: The use of antihistamines in asthma. Annals of Allergy 30: 342–347 (1972).PubMedGoogle Scholar
  62. Kniker, W.T.; Guerra, F.A. and Richards, S.E.M.: Prevention of immune complex disease (serum sickness) by antagonists by vasoactive amines. Pediatric Research 5: 381 (1971) (abstract).Google Scholar
  63. Knowles, J.A.: Excretion of drugs in milk — a review. Journal of Pediatrics 66: 1068–1082 (1965).PubMedGoogle Scholar
  64. Kraft, E. and Zimmerman, B.G.: Influence of histamine H1 — and H2-receptor blockers on sympathetic vasodilator and vasoconstrictor responses in canine paw. British Journal of Pharmacology 53: 51–58 (1975).PubMedGoogle Scholar
  65. Kuntzman, R.: Drugs and enzyme induction. Annual Review of Pharmacology 9: 21–36 (1969).PubMedGoogle Scholar
  66. Landerman, N.S.: Hereditary angioneurotic edema. I. Case reports and review of the literature. Journal of Allergy 33: 316–329 (1962).PubMedGoogle Scholar
  67. Leavitt, M.D. and Code, CF.: A study of the action of beta-dimethylaminoethyl benzhydryl ether hydrochloride (Benadryl) in the skin of human beings. Journal of Laboratory and Clinical Medicine 32: 334–335 (1947).PubMedGoogle Scholar
  68. Legge, D.A.; Tiede, J.J.; Peters, G.A. and Gedge, S.W.: Death from tension pneumothorax and chlorpromazine cardiorespiratory collapse as separate complications of asthma. Annals of Allergy 27: 23–29 (1969).PubMedGoogle Scholar
  69. Lichtenstein, L.M. and Gillespie, E.: Inhibition of histamine release by histamine is controlled by an H2-receptor. Nature (Lond.) 244: 287–288 (1973).Google Scholar
  70. Loew, E.R.: Pharmacology of antihistamine compounds. Physiological Reviews 7: 542–573 (1947).Google Scholar
  71. Loew, E.R.: The pharmacology of Benadryl and the specificity of antihistamine drugs. Annals of the New York Academy of Sciences 123: 1142–1160 (1950).Google Scholar
  72. Loew, E.R.; MacMillan, R. and Kaiser, M.E.: The antihistamine properties of Benadryl, a β-dimethylameroethyl benzhydryl ethyl hydrochloride. J. Pharmacol, exp. Ther. 86: 229–238 (1946).Google Scholar
  73. Lorriman, G. and Martin, W.J.: Trial of Antistin in the common cold. Brit. med. J. 2: 430–431 (1950).PubMedGoogle Scholar
  74. Loveless, M.H. and Dworin, M.: Allergy and antihistamine therapy. A review. Bulletin of the New York Academy of Medicine 25: 473–487 (1949).Google Scholar
  75. Mainardi, M.; Maxwell, V.; Sturdevant, R.A.L. and Isenberg, J.I.: Inhibition of gastric acid secretion by metiamide in Zollinger Ellison syndrome. American Journal of Digestive Diseases 20: 280–281 (1975).PubMedGoogle Scholar
  76. Martin, E.W.; Alexander, S.F.; Farage, D.J. and Hassan, W.E. (Eds) Hazards of Medication, chapter 8, Patient response, p.216–320 (Lippincott, Philadelphia 1971).Google Scholar
  77. Matthews, C.N.A.; Kirby, J.A.; James, J. and Warin, R.P.: Dermographism: reduction in wheal size by chlorpheniramine and hydroxyzine. British Journal of Dermatology 88: 279–282 (1973).PubMedGoogle Scholar
  78. Mellin, G.W.: Drugs in the first trimester of pregnancy and the fetal life of Homo sapiens. American Journal of Obstetrics and Gynecology 90: 1169–1180 (1964).PubMedGoogle Scholar
  79. Melville, K.: Antihistamine drugs; in Schachter (Ed) Histamine and Antihistamines. International Encyclopedia of Pharmacology and Therapeutics, p.127–171 (Pergammon Press, New York 1973).Google Scholar
  80. Mosko, M.M. and Peterson, W.L.: Sensitization to Antistine. Journal of Investigative Dermatology 14: 1–2(1950).PubMedGoogle Scholar
  81. Mota, I. and Dias de Silva, W.: The anti-anaphylactic and histamine releasing properties of the anti-histaminics. Their effects on the mast cells. British Journal of pharmacology and Therapeutics 15: 396–404 (1960).Google Scholar
  82. Naranjo, P. and Banda de Naranjo, E.: Studies of the combined action of some antihistaminic agents. Annals of Allergy 11: 699–716 (1953).PubMedGoogle Scholar
  83. Nicholson, P.A. and Bogie, W.: Diurnal variations in the symptoms of hay fever; implications for pharmaceutical development. Current Medical Research Opinion 1: 395–400(1973).Google Scholar
  84. Nickerson, M.: Receptor occupancy and tissue response. Nature (Lond.) 178: 697–698 (1956).Google Scholar
  85. Nickerson, M. and Collier, B.: Drugs inhibiting adrenergic nerves and structures innervated by them; in Goodman and Gilman (Eds) The Pharmacological Basis of Therapeutics, chapter 27, p.533–564, 5th ed. (Macmillan, New York 1975).Google Scholar
  86. Parrot, T.L.: Syndrome histaminique et antagonistes de l’histamine. Presse Medicale 50: 771–772 (1942).Google Scholar
  87. Pearlman, D.S.: Allergic disorders; in Stiehm and Fulginiti (Eds) Immunologic Disorders in Infants and Children, chapter 19, p.333–369 (Saunders, Philadelphia 1973).Google Scholar
  88. Plaut, M.; Lichtenstein, L.M.; Gillespie, F. and Henney, C.S.: Studies on the mechanism of lymphocytemediated cytolysis. IV. Specificity of the histamine receptor on effector T cells. Journal of Immunology 111: 389–394 (1973a).Google Scholar
  89. Plaut, M.; Lichtenstein, L.M. and Henney, C: Increase in histaminic receptors on thymus-derived effector lymphocytes during the 1° immune response to all antigens. Nature (Lond.) 244: 284–286 (1973b).PubMedGoogle Scholar
  90. Pockedly, C. and Ente, G.: Adverse hematologie effects of drugs. Pediatrie Clinics of North America 19: 1095–1111 (1972).Google Scholar
  91. Powell, J.R. and Brody, M.J.: Identification of two vascular histamine receptors in the dog; in Wood and Simkins (Eds) International Symposium on H2-receptor Antagonists, p.137–146 (Smith Kline and French, Welwyn Garden City 1973).Google Scholar
  92. Rocha e Silva, M.: Kinin Hormones (Thomas, Springfield, Ill. 1970).Google Scholar
  93. Roth, F.E. and Tabachnick, I.I.A.: Histamine and antihistamines; in Di Palma (Ed) Drills Pharmacology in Medicine, chapter 48, p.995–1020 (McGraw-Hill, New York 1971).Google Scholar
  94. Schild, H.O.: Histamine release and anaphylaxis; in Wolstenholme and O’Connor (Eds) Ciba Foundation Symposium on Histamine, p.139–149 (Little Brown, Boston 1956).Google Scholar
  95. Simonsson, B.G.: Effect of Multergan on ventilatory capacities in patients with generalized airways obstruction. Acta Allergologica 19: 305–310 (1964).PubMedGoogle Scholar
  96. Staszewska-Barczak, J. and Vane, J.R.: The release of catecholamines from the adrenal medulla by histamine. British Journal of pharmacology and Chemotherapy 25: 728–742 (1965).PubMedGoogle Scholar
  97. Stone, CA.; Wenger, H.C.; Ludden, C.T.; Stavorski, J.M. and Ross, C.S.: Antiserotonin: antihistaminic properties of cyproheptadine. Journal of Pharmacology and Experimental Therapeutics 131: 73–94 (1961).Google Scholar
  98. Tuft, L.: Allergy Management in Clinical Practice (Mosby, St. Louis 1973).Google Scholar
  99. Valic F. and Zuskin, E.: Pharmacological prevention of acute ventilatory capacity reduction in flax dust exposure. British Journal of Industrial Medicine 30: 381–384 (1973).PubMedGoogle Scholar
  100. Vaughan, V.C III: Allergic disorders; in Nelson, Vaughan and McKay (Eds) Textbook of Pediatrics, p.488–510, 9th ed. (Saunders, Philadelphia 1969).Google Scholar
  101. Wanderer, A.A. and Ellis, E.F.: Treatment of cold urticaria with cyproheptadine. Journal of Allergy and Clinical Immunology 4: 367–371 (1971).Google Scholar
  102. Warin, R.P. and Champion, R.H.: Urticaria (Saunders, London 1974).Google Scholar
  103. Wilhelm, R.E.: The newer anti-allergic agents. Medical Clinics of North America 45: 887–906 (1961).PubMedGoogle Scholar
  104. Wilhelm, R.E.; Nutting, H.M.; Devlin, H.B.; Jennings, E.R. and Brines, O.A.: Antihistamines in allergic and pyrogenic transfusion reactions. Journal of the American Medical Association 158: 529–531 (1955).PubMedGoogle Scholar
  105. Winder, C.V.; Kaiser, M.E.; Anderson, M.M. and Glassco, E.M.: Myotropic spasmolytic, histaminolytic, and atropine-like actions of some derivatives of dimethylaminolthyl benzhydryl ether hydrochloride (Benadryl). Journal of Pharmacology and Experimental Therapeutics 87: 121–131 (1946).PubMedGoogle Scholar
  106. Wyngaarden, J.B. and Seevers, M.H.: The toxic effects of antihistaminic drugs. Journal of the American Medical Association 145: 277–282 (1951).PubMedGoogle Scholar
  107. Yu, D.Y.C.; Galant, S.O. and Gold, W.M.: Inhibition of antigen-induced bronchoconstriction by atropine in asthmatic patients. Journal of Applied Physiology 32: 823–828 (1972).PubMedGoogle Scholar
  108. Zweiman, B.; Mishkin, M.M. and Hildreth, E.A.: An approach to the performance of contrast studies in contrast material-reactive persons. Annals of Internal Medicine 83: 159–162 (1975).PubMedGoogle Scholar

Copyright information

© ADIS Press 1976

Authors and Affiliations

  • David S. Pearlman
    • 1
    • 2
  1. 1.Department of PediatricsThe National Jewish Hospital and Research CenterDenverUSA
  2. 2.University of Colorado Medical CenterDenverUSA

Personalised recommendations